Shilpa Medicare's Irinotecan injection is used to treat patients with metastatic cancer of the colon or rectum.
Moneycontrol News
@moneycontrolcom
Shares of Shilpa Medicare rose over 3.5 percent in early trade on January 1 after the company received FDA approval for its Irinotecan injection.
The stock gained as much as 4.5 percent on the BSE, quoting at Rs 401.3.
The US Food and Drug Administration (USFDA) gave the company approval for its ANDA Irinotecan HCL Injection USP, 40 mg/2mL and 100 mg/5mL (20mg/mL) single dose vials.
Irinotecan injection is used to treat patients with metastatic cancer of the colon or rectum.
At 09:47 hrs, Shilpa Medicare was quoting at Rs 398.15 on the BSE, up 3.67 percent.First Published on Jan 1, 2019 09:52 am
